PURPOSE: NKG2D (natural killer group 2, member D) binds to cellular ligands of the MIC and ULBP/RAET family. These ligands have restricted expression in normal tissue, but are frequently expressed on primary tumors. The role of NKG2D ligands is thought to be important in carcinogenesis but its prognostic effect has not been investigated in such a large cohort. EXPERIMENTAL DESIGN: In our study, 462 primary colorectal tumors were screened for the expression of all MIC/ULBP/RAET proteins and NK cell infiltration. Tumor microarray technology was used for the purpose of this investigation. RESULTS: NKG2D ligands were expressed by the majority of colorectal tumors; however, the level of expression varied considerably. High expression of MIC (68 versus 56 months) or RAET1G (74 versus 62 months) showed improved patient survival. Tumors expressing high levels of MIC and RAET1G showed improved survival of 77 months over tumors that expressed high levels of one ligand or low levels of both. High-level expression of all ligands was frequent in tumor-node-metastasis stage I tumors, but became progressively less frequent in stages II, III, and IV tumors. Expression of MIC was correlated with NK cellular infiltration. CONCLUSION: The observations presented are consistent with an immunoediting mechanism that selects tumor cells that have lost or reduced their expression of NKG2D ligands. The combination of MIC and tumor-node-metastasis stage was found to be the strongest predictor of survival, splitting patients into eight groups and suggesting prognostic value in clinical assessment. Of particular interest were stage I patients with low expression of MIC who had a similar survival to stage III patients, and may be candidates for adjuvant therapy.
PURPOSE:NKG2D (natural killer group 2, member D) binds to cellular ligands of the MIC and ULBP/RAET family. These ligands have restricted expression in normal tissue, but are frequently expressed on primary tumors. The role of NKG2D ligands is thought to be important in carcinogenesis but its prognostic effect has not been investigated in such a large cohort. EXPERIMENTAL DESIGN: In our study, 462 primary colorectal tumors were screened for the expression of all MIC/ULBP/RAET proteins and NK cell infiltration. Tumor microarray technology was used for the purpose of this investigation. RESULTS:NKG2D ligands were expressed by the majority of colorectal tumors; however, the level of expression varied considerably. High expression of MIC (68 versus 56 months) or RAET1G (74 versus 62 months) showed improved patient survival. Tumors expressing high levels of MIC and RAET1G showed improved survival of 77 months over tumors that expressed high levels of one ligand or low levels of both. High-level expression of all ligands was frequent in tumor-node-metastasis stage I tumors, but became progressively less frequent in stages II, III, and IV tumors. Expression of MIC was correlated with NK cellular infiltration. CONCLUSION: The observations presented are consistent with an immunoediting mechanism that selects tumor cells that have lost or reduced their expression of NKG2D ligands. The combination of MIC and tumor-node-metastasis stage was found to be the strongest predictor of survival, splitting patients into eight groups and suggesting prognostic value in clinical assessment. Of particular interest were stage I patients with low expression of MIC who had a similar survival to stage III patients, and may be candidates for adjuvant therapy.
Authors: Mirjana Radosavljevic; Benoît Cuillerier; Michael J Wilson; Oliver Clément; Sophie Wicker; Susan Gilfillan; Stephan Beck; John Trowsdale; Seiamak Bahram Journal: Genomics Date: 2002-01 Impact factor: 5.736
Authors: Robert A Eagle; Gillian Flack; Anthony Warford; Jesús Martínez-Borra; Insiya Jafferji; James A Traherne; Maki Ohashi; Louise H Boyle; Alexander D Barrow; Sophie Caillat-Zucman; Neil T Young; John Trowsdale Journal: PLoS One Date: 2009-02-18 Impact factor: 3.240
Authors: A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez Journal: Genes Immun Date: 2014-11-13 Impact factor: 2.676
Authors: Elena Catalán; Seyma Charni; Paula Jaime; Juan Ignacio Aguiló; José Antonio Enríquez; Javier Naval; Julián Pardo; Martín Villalba; Alberto Anel Journal: Oncoimmunology Date: 2015-02-03 Impact factor: 8.110
Authors: Claire Godbersen; Tiffany A Coupet; Amelia M Huehls; Tong Zhang; Michael B Battles; Jan L Fisher; Marc S Ernstoff; Charles L Sentman Journal: Mol Cancer Ther Date: 2017-05-12 Impact factor: 6.261
Authors: Gang Liu; Shengjun Lu; Xuanjun Wang; Stephanie T Page; Celestia S Higano; Stephen R Plymate; Norman M Greenberg; Shaoli Sun; Zihai Li; Jennifer D Wu Journal: J Clin Invest Date: 2013-09-09 Impact factor: 14.808
Authors: Carlos Peinado; Xi Kang; Chanae Hardamon; Sumit Arora; Stephen Mah; Hui Zhang; Jennifer Ngolab; Jack D Bui Journal: Immunology Date: 2013-06 Impact factor: 7.397